fashion -WSS

fashion

author：comprehensive 2025-09-30 18:00:43 - browse：43

Travere Therapeutics said Thursday that a study meant to confirm the benefit of its newly approved drug for a rare kidney disorder narrowly failed.

In the trial, 404 patients with the disorder, IgA nephropathy, were randomized to receive either Travere’s daily pill, Filspari, or irbesartan, a decades-old blood pressure drug often used to help manage the disease. Early data had showed the drug cut protein levels in the urine, a biomarker of kidney function, by half after nine months. That convinced regulators to give Filspari accelerated approval in February, pending full results using a more direct measure of kidney function.

The new data, after 24 months, showed that patients who received Filspari declined less quickly than those in the control group. But the results just missed statistical significance, with a P value of 0.058.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Trump’s hydroxychloroquine hype: a risk to my treatment and to him

WSS

Lupron, used to halt puberty in children, may cause lasting health problems

Security flaws in third

Being 'nonadherent' patient made me a more empathetic doctor

Presidential candidate assassinated in Ecuador, 1 suspect dead and 6 arrested

Where are patients getting their prescriptions for GLP

The perfect storm of weather conditions that led to the devastating wildfires in Maui

Wikipedia

fashion

focus

ChatGPT in medicine: STAT answers readers' burning questions

Hubble vs. James Webb telescope images: See the difference

Activists slam private health insurers over coverage restrictions

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

Medicare details structure of new drug price negotiation program

'Screen and refer' systems are hurting patients

BioMarin wins approval for gene therapy to treat hemophilia A

Listen: Your guide to Wegovy's blockbuster heart study

BioMarin wins approval for gene therapy to treat hemophilia A

Novo acquires Inversago for up to $1 billion

explore

The biotech scorecard for Q3: 15 stock

TB outbreak tied to bone grafts underscores testing shortcomings

Large hospital system sues Multiplan for low

Vertex cell therapy lets patients with type 1 diabetes stop insulin

Being 'nonadherent' patient made me a more empathetic doctor

UpToDate has a racism problem: Dr. Stanley Goldfarb

Wikipedia

Wikipedia

entertainment

knowledge